Acepodia Partners with Pfizer to Accelerate Development of Autoimmune ACC Therapies

Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.

On September 3, Acepodia, a clinical-stage biotechnology company, is developing first-in-class cell therapies using its unique Antibody-Conjugated Cell (ACC) and allogeneic γδ2 T-cell platforms. Pfizer Ignite is an end-to-end service that leverages Pfizer's extensive resources, scale, and expertise, along with its proven track record in delivering breakthrough innovations, to support biotech companies in accelerating their innovation process from preclinical R&D through the entire development lifecycle.

According to the new agreement, Pfizer Ignite will focus on the development of oncology at Acepodia, Inc.Provide strategic guidance and resources in the process of cell therapy for autoimmune diseases.

Acepodia’s ACC Platform Utilizes Bioorthogonal Chemistry, Building on the Groundbreaking Work of 2022 Nobel Prize Winner Dr. Carolyn Bertozzi, Applying Click Chemistry to Living Systems to Create an Off-the-Shelf, Non-Genetically Engineered Version of CAR-T Cell Therapy That Is Easier to Deploy and Avoids Cytokine Release Syndrome, Neurotoxicity, and Other Side Effects Associated with CAR-T Cell Therapy. Acepodia’s Lead Clinical Candidate, ACE1831, Is Currently Being Evaluated in a Phase I First-in-Human Clinical Trial for Patients with Non-Hodgkin Lymphoma, Demonstrating Strong and Durable Efficacy After a Single Treatment at the Lowest Dose.

Through the collaboration with Pfizer Ignite, Acepodia will benefit from Pfizer's resources, deep expertise, and R&D capabilities, covering multiple stages such as clinical trial design and regulatory strategy, thereby improving the development process of innovative drugs.

PfizerIgniteThe plan focuses on supporting the delivery of innovative therapies that align with Pfizer's strategic priorities and have the potential to address significant gaps in patient care. PfizerIgniteSenior Vice President and HeadKathy FernandoSaid: "Relying on Pfizer's deep expertise in oncology and immunology, we look forward to collaborating with Acepodia to help transform their compelling scientific platform into new medicines for patients with unmet needs."

Reference: Company Announcement